



IAP7 Rec'd PCT/P

06 FEB 2006 615

Atty. Dkt. No. SPRUS1140
(026470-0501)

#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hill et al.
Title: CHAPERONIN 10
IMMUNOSUPPRESSION
Appl. No.: 10/534,193
Filing Date: May 6, 2005
Examiner: Not yet assigned
Art Unit: 1615
Conf. No. 9978

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
Stephen E. Reiter	(Printed Name)
	(Signature)
7/1/06	(Date of Deposit)

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment-IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to

026470-0500

antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 7/1/06

By Stephen E. Reiter

FOLEY & LARDNER LLP
Customer Number: 30542
Telephone: (858) 847-6711
Facsimile: (858) 792-6773

Stephen E. Reiter
Attorney for Applicant
Registration No. 31,192

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/534,193
Filing Date	May 6, 2005
First Named Inventor	Hill et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	SPRUS1140 (026470-0501)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	95/15338		The University of Queensland	06-08-1995		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A2	CHEN et al., "Isolation, sequence analysis and characterization of a cDNA encoding human chaperonin 10" Biochim. Biophys. Acta, 1219, 189-190 (1994)	
	A3	COOKE et al., "LPS antagonism reduces graft-versushost disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation." J. Chin. Invest., 107, 1581-1589 (2001)	
	A4	COOKE et al, "Hyporesponsiveness of Donor Cells to Lipopolysaccharide Stimulation Reduces the Severity of Experimental Idiopathic Pneumonia Syndrome: Potential Role for a Gut-Lung Axis of Inflammation." J. Immunol., 165, 6612-6619, (2000)	
	A5	COOKE et al, "An Experimental Model of Idiopathic Pneumonia Syndrome After Bone Marrow Transplantation: I. The Roles of Minor H Antigens and Endotoxin." Blood, 88, 3230-3239 (1996)	
	A6	DICKSON et al., "Cloning, Expression, and Purification of a Functional Nonacetylated Mammalian Mitochondrial Chaperonin 10." J. Biol. Chem., 269, 26858-864, (1994)	
	A7	ELLIS et al., "Molecular Chaperones." Annu. Rev. Biochem. 60, 321-47, (1991)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/534,193
		Filing Date	May 6, 2005
		First Named Inventor	Hill et al.
		Group Art Unit	
		Examiner Name	
Sheet	2	of	3
		Attorney Docket Number	SPRUS1140 (026470-0501)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A8	HARTMAN et al., "Identification of a mammalian 10-kDa heat shock protein, a mitochondrial chaperonin 10 homologue essential for assisted folding of trimeric ornithine transcarbamoylase <i>in vitro</i> ." Proc. Natl. Acad. Sci. USA, 89, 3394-8, (1992)	
	A9	HILL et al., "Interleukin-11 Promotes T Cell Polarization and Prevents Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation." J. Clin. Invest., 102, 115-123 (1998)	
	A10	HILL et al., "Total Body Irradiation and Acute Graft-Versus-Host disease: The role of Gastrointestinal Damage and Inflammatory Cytokines." Blood, 90, 3204-3213, (1997)	
	A11	HILL et al., "Differential roles of IL-1 and TNF- α on graft-versus-host disease and graft versus leukemia." J. Clin. Invest., 104, 459-467, (1999)	
	A12	KRIJANOVSKI et al., "Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease." Blood, 94, 825-831, (1999)	
	A13	MORTON et al., "Immunosuppression detected in pregnant mice by rosette inhibition test." Nature, 249; 459-460; (1974)	
	A14	MORTON et al., "Studies of the Rosette Inhibition Test in Pregnant Mice: Evidence of Immunosuppression?" Proc. R. Soc. Lond., 193; 413-9, (1976)	
	A15	MORTON et al., "Recent Advances in Mammalian Development." Current Topics in Developmental Biology, 23; 73-92 (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. **06**

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT FEB 06 7 (use as many sheets as necessary)		Complete if Known	
		Application Number	10/534,193
		Filing Date	May 6, 2005
		First Named Inventor	Hill et al.
		Group Art Unit	
		Examiner Name	
Sheet	3	of	3
		Attorney Docket Number	SPRUS1140 (026470-0501)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A16	MORTON H., "Early pregnancy factor: An extracellular chaperonin 10 homologue." Immunol. Cell Biol., 76, 483-496, (1998)	
	A17	NOONAN et al., "Early pregnancy factor is immunosuppressive." Nature, 278, 649-51, (1979)	
	A18	OGITA et al., "Stress Responses in Graft and Native Intestine After Rat Heterotopic Small Bowel Transplantation." Transplantation, 69, 2273-2277, (2000)	
	A19	ROLFE et al., "Identification of two suppressor factors induced by early pregnancy factor." Clin. Exp. Immunol., 73, 2 19-225, (1988)	
	A20	RYAN et al., "Isolation of a cDNA clone specifying rat chaperonin 10, a stress-inducible mitochondrial matrix protein synthesised without a cleavable presequence." FEBS Lett., 337, 152-156 (1994)	
	A21	SPEISER et al., "TNF Receptor p55 Controls Early Acute Graft-Versus-Host Disease." J. Immunol., 158, 5185-5190, (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.